U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07198867) titled 'A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia' on July 30.
Brief Summary: This is a single-center, open-label study to evaluate the safety and efficacy of A-CAR028 in relapsed/refractory acute myeloid leukemia patients
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukemia (AML)
CAR-T Cell Therapy
Intervention:
BIOLOGICAL: A-CAR028
A-CAR028 is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD33 and CLL-1 antigens
Recruitment Status: RECRUITING
Sponsor: First Affiliated Hospital of Zhejiang Universi...